Nevertheless, disappointing results from the clinical trials of EGFR-targeted therapies for CRC raise uncertainties about the significance of the EGFR signaling pathway in the patients specifically harboring KRAS, NRAS and BRAF mutations. The gene discussed is KRAS; the disease is colorectal carcinoma.